RxDoctor Payments Data

Masha Nakelchik, MD

Internal Medicine · San Jose, CANPI 1255346623

Payments from drug & device makers

$23,722in general payments, 2019–2025

Across 1,241 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • Pfizer$2K
  • Amgen$1K
  • GSK$1K
  • AstraZeneca$1K
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$23,40299%
  • Education$3201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)204$3,426
Novo Nordisk128$1,865
Pfizer102$1,818
Amgen64$1,372
GSK66$1,350
AstraZeneca(2 entities)61$1,277
Lilly USA, LLC70$1,218
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)44$1,029
Mylan Specialty L.p.30$762
Astellas Pharma US Inc24$650
Amarin Pharma, Inc.37$638
Radius Health, Inc.24$583
Merck29$552
Boehringer Ingelheim45$460
Abbott14$422
Sunovion Pharmaceuticals Inc.26$401
Otsuka America Pharmaceutical, Inc.17$366
Exact Sciences15$330
Bayer12$310
Axsome Therapeutics, Inc.12$300
Johnson & Johnson14$294
Sumitomo Pharma America, Inc.14$271
Idorsia Pharmaceuticals US Inc9$204
Novartis9$190
Hikma Pharmaceuticals USA11$189
Biohaven Pharmaceutical Holding Company Ltd.8$180
IBSA Pharma Inc.8$162
Teva Pharmaceuticals USA, Inc.7$158
Biohaven Pharmaceuticals, Inc.7$147
Dexcom, Inc.6$142
Madrigal Pharmaceuticals4$137
Sanofi-aventis U.S. LLC7$133
Esperion Therapeutics, Inc.6$129
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$128
Electromed, Inc.8$122
Eisai Inc.6$118
Neurocrine Biosciences, Inc.5$114
Seqirus USA Inc5$113
Vanda Pharmaceuticals Inc.3$108
Avanir Pharmaceuticals, Inc.4$104
Kowa Pharmaceuticals America, Inc.5$89
Arbor Pharmaceuticals, Inc.4$82
Takeda Pharmaceuticals U.S.A., Inc.4$77
Sanofi Pasteur Inc.3$74
Jazz Pharmaceuticals Inc.4$70
Philips North America LLC3$67
Phathom Pharmaceuticals, Inc.2$65
Aimmune Therapeutics, Inc.2$61
ANI Pharmaceuticals, Inc.2$57
Alfasigma USA, Inc.3$57
Zyla Life Sciences, Inc.3$56
Corium, LLC2$55
Nestle Healthcare Nutrition Inc.2$54
Redhill Biopharma Inc.3$47
Amneal Pharmaceuticals LLC2$47
Intercept Pharmaceuticals, Inc.2$43
Bausch Health US, LLC2$43
Paratek Pharmaceuticals, Inc.2$37
Viiv Healthcare Company2$37
Indivior Inc.1$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,722 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$231,539
Medicare patients
384
Services billed
1,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin173$221,537
OzempicSemaglutide133$149,994
EliquisApixaban103$139,876
FarxigaDapagliflozin Propanediol67$68,890
JanuviaSitagliptin Phosphate46$57,920
TrulicityDulaglutide43$55,736
KerendiaFinerenone27$45,309
TradjentaLinagliptin53$39,908
MounjaroTirzepatide39$39,078
RybelsusSemaglutide19$35,855
LinzessLinaclotide21$28,623
ProliaDenosumab16$27,230
Breo ElliptaFluticasone/Vilanterol55$24,345
GemtesaVibegron30$22,957
Nurtec OdtRimegepant Sulfate11$20,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$460$261,445226 claims
Novo NordiskOzempic, Rybelsus$1,865$185,848152 claims
PfizerEliquis, Nurtec Odt$1,818$160,179114 claims
Lilly USA, LLCTrulicity, Mounjaro$1,218$94,81482 claims
AstraZenecaFarxiga, Symbicort$1,277$71,86580 claims
MerckJanuvia, Belsomra$552$64,08060 claims
BayerKerendia$310$45,30927 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$1,350$43,77885 claims
AbbVieLinzess$3,426$28,62321 claims
AmgenProlia$1,372$27,23016 claims
Sumitomo Pharma America, Inc.Gemtesa$271$22,95730 claims
Johnson & JohnsonXarelto$294$19,39617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →